




## Diagnostics

### Kit for the diagnosis of allergy to pyrazolones

A research group from the Andalusian Public Health System (SSPA) has developed a set of metabolites for its use in the manufacture of a kit for the diagnosis of selective hypersensitivity to pyrazolone.

Oficina de  
**TRANSFERENCIA  
DE TECNOLOGÍA**  
Sistema Sanitario Público de Andalucía



#### Description

Allergic reactions to drugs constitute an important public health problem, causing 5% of hospitalizations. Nonsteroidal antiinflammatory drugs (NSAIDs) are the most common cause of allergic reactions to drugs, many of which are induced by hypersensitivity mechanisms from both immune and non-immune origin. Inside the reactions of mediated by IgE immune origin, the selective allergic reactions to pirazolonas are the most common, specifically the metamizol.

Currently, the diagnosis of selective hypersensitivity to pyrazolone is mainly based on the clinical history, skin testing and oral provocation test. But it is necessary to have a validated in vitro method safer and more direct, since the skin test has low sensitivity and the oral challenge test may cause secondary effects. Although the basophil activation test (BAT) has been proposed as a new diagnostic tool that has proven to be a good complement to the skin test for the evaluation of the immediate allergic reaction to pirazolonas, the sensitivity obtained so far using dipyrone as hapten is low.

As a solution to the problems of in vitro methods currently available, regarding the lack of sensitivity, the research group has identified a series of compounds useful as antigens for the development of a new diagnostic kit of hypersensitivity (selective) to pyrazolones with an adequate degree of sensitivity.

The developed kit has been validated by a study with over 100 patients.



#### Advantages

The main advantage of the use of the compounds identified as antigens in the basophil activation test, or other in vitro method, for the diagnosis of selective hypersensitivity to pyrazolones, is the greatly enhancing of the sensitivity compared to currently available methods.



#### Intellectual Property

The technology is protected by patent.



#### Aims

The research group is looking for a license or a collaboration agreement.



#### Classification

Area: Diagnostic

Pathology: Autoimmune and Inflammation



JUNTA DE ANDALUCÍA  
CONSEJERÍA DE IGUALDAD, SALUD Y POLÍTICAS SOCIALES



**FIMABIS**  
FUNDACIÓN PÚBLICA ANDALUZA  
PARA LA INVESTIGACIÓN DE MÁLAGA  
EN BIOMEDICINA Y SALUD

Avda. Jorge Luis Borges, 15. bloque 3, 3º 29010. Málaga. SPAIN

+34 951 440 260 +34 951 440 263 [isabel.guerrero@fimabis.org](mailto:isabel.guerrero@fimabis.org)

[www.fimabis.org](http://www.fimabis.org)